Influence of underfill materials on the reliability of coreless flip chip package

Chun-Chih Chuang,Tsung-Fu Yang,J. Juang,Yin-Po Hung,C. Zhan,Yu-Min Lin,Ching-Tsung Lin,P. Chang,Tao-Chih Chang

DOI: https://doi.org/10.1016/j.microrel.2008.09.005

2008-11-01

Abstract:

What problem does this paper attempt to address?

Menopause and High Altitude: A Scoping Review-UIAA Medical Commission Recommendations

Kastė Mateikaitė-Pipirienė,Dominique Jean,Peter Paal,Lenka Horakova,Susi Kriemler,Alison J Rosier,Marija Andjelkovic,Beth A Beidleman,Mia Derstine,Jacqueline Pichler Hefti,David Hillebrandt,Linda E Keyes

DOI: https://doi.org/10.1089/ham.2023.0039

Abstract:Mateikaitė-Pipirienė, Kastė, Dominique Jean, Peter Paal, Lenka Horakova, Susi Kriemler, Alison J. Rosier, Marija Andjelkovic, Beth A. Beidleman, Mia Derstine, Jacqueline Pichler Hefti, David Hillebrandt, and Linda E. Keyes for the UIAA MedCom writing group on Women's Health in the Mountains. Menopause and high altitude: A scoping review-UIAA Medical Commission Recommendations. High Alt Med Biol. 25:1-8, 2024. Background: Older people are an important fraction of mountain travelers and climbers, many of them postmenopausal women. The aim of this work was to review health issues that older and postmenopausal women may experience at high altitude, including susceptibility to high-altitude illness. Methods: We performed a scoping review for the UIAA Medical Commission series on Women's Health in the mountains. We searched PubMed and Cochrane libraries and performed an additional manual search. The primary search focused on articles assessing lowland women sojourning at high altitude. Results: We screened 7,165 potential articles. The search revealed three relevant articles, and the manual search another seven articles and one abstract. Seven assessed menopausal low-altitude residents during a high-altitude sojourn or performing hypoxic tests. Four assessed high-altitude residents. We summarize the results of these 11 studies. Conclusions: Data are limited on the effects of high altitude on postmenopausal women. The effects of short-term, high-altitude exposure on menopause symptoms are unknown. Menopause has minimal effect on the physiological responses to hypoxia in physically fit women and does not increase the risk of acute mountain sickness. Postmenopausal women have an increased risk of urinary tract infections, which may be exacerbated during mountain travel. More research is needed on the physiology and performance of older women at high altitude.
Characteristics and enantiomeric analysis of chiral pyrethroids.

V. Pérez‐Fernández,Maria A. García,M. Marina

DOI: https://doi.org/10.1016/j.chroma.2009.10.069

IF: 4.601

2010-02-12

Journal of Chromatography A

Abstract:
Research advances in pathogenesis and prophylactic measures of acute high altitude illness

Yunhong Li,Yujing Zhang,Ying Zhang

DOI: https://doi.org/10.1016/j.rmed.2018.11.004

IF: 4.3

2018-01-01

Respiratory Medicine

Abstract:After ascent to high altitude (≥2500 m), the inability of the human body to adapt to the hypobaric and hypoxia environment can induce tissue hypoxia, then a series of high altitude illnesses including acute mountain sickness (AMS), high altitude pulmonary edema (HAPE), and high altitude cerebral edema (HACE) would develop. Symptoms of AMS include headache, dizziness, nausea, and vomiting; HAPE is characterized by orthopnea, breathlessness at rest, cough, pink frothy sputum, and results in obvious pulmonary edema that poses significant harm to people; HACE is characterized by ataxia and decreased consciousness, leading to coma and brain herniation which would be fatal if not treated promptly. This review article provides a current understanding of the pathophysiology of these three forms of high altitude illness and elaborates the current prevention and treatment measures of these diseases.
Hormonal Contraception and Menstrual Cycle Control at High Altitude: A Scoping Review-UIAA Medical Commission Recommendations

Lenka Horakova,Susi Kriemler,Vladimír Študent,Jacqueline Pichler Hefti,David Hillebrandt,Dominique Jean,Kastė Mateikaitė-Pipirienė,Peter Paal,Alison Rosier,Marija Andjelkovic,Beth Beidlemann,Mia Derstine,Linda E Keyes

DOI: https://doi.org/10.1089/ham.2024.0021

2024-04-12

Abstract:Horakova, Lenka , Susi Kriemler, Vladimír Študent, Jacqueline Pichler Hefti, David Hillebrandt, Dominique Jean, Kastė Mateikaitė-Pipirienė, Peter Paal, Alison Rosier, Marija Andjelkovic, Beth Beidlemann, Mia Derstine, and Linda E. Keyes. Hormonal contraception and menstrual cycle control at high altitude: a scoping review-UIAA Medical Commission recommendations. High Alt Med Biol. 00:00-00, 2024. Background: Women who use hormonal contraception (HC) may have questions about their use during travel to high altitude. This scoping review summarizes current evidence on the efficacy and safety of HC and cycle control during high-altitude travel. Methods: We performed a scoping review for the International Climbing and Mountaineering Federation (UIAA) Medical Commission series on Women's Health in the Mountains. Pertinent literature from PubMed and Cochrane was identified by keyword search combinations (including contraception) with additional publications found by hand search. Results: We identified 17 studies from 7,165 potentially eligible articles. No articles assessed the efficacy of contraception during a short-term high-altitude sojourn. Current data show no advantage or disadvantage in HC users for acclimatization or acute mountain sickness (AMS). Use of HC during high-altitude travel is common and safe for menses suppression. A potential concern of estrogen-containing HC is the increased thrombotic risk, which theoretically could be compounded in hypobaric hypoxia. Conclusions: Evidence is limited for the interaction of HC and high altitude on performance, thrombosis, and contraceptive efficacy. HC does not affect the risk of AMS. The most efficacious and safest method at high altitude is generally the one women are most familiar with and already using.
Altitude illnesses

Hannes Gatterer,Francisco C. Villafuerte,Silvia Ulrich,Sanjeeb S. Bhandari,Linda E. Keyes,Martin Burtscher

DOI: https://doi.org/10.1038/s41572-024-00526-w

IF: 81.5

2024-06-21

Nature Reviews Disease Primers

Abstract:Millions of people visit high-altitude regions annually and more than 80 million live permanently above 2,500 m. Acute high-altitude exposure can trigger high-altitude illnesses (HAIs), including acute mountain sickness (AMS), high-altitude cerebral oedema (HACE) and high-altitude pulmonary oedema (HAPE). Chronic mountain sickness (CMS) can affect high-altitude resident populations worldwide. The prevalence of acute HAIs varies according to acclimatization status, rate of ascent and individual susceptibility. AMS, characterized by headache, nausea, dizziness and fatigue, is usually benign and self-limiting, and has been linked to hypoxia-induced cerebral blood volume increases, inflammation and related trigeminovascular system activation. Disruption of the blood–brain barrier leads to HACE, characterized by altered mental status and ataxia, and increased pulmonary capillary pressure, and related stress failure induces HAPE, characterized by dyspnoea, cough and exercise intolerance. Both conditions are progressive and life-threatening, requiring immediate medical intervention. Treatment includes supplemental oxygen and descent with appropriate pharmacological therapy. Preventive measures include slow ascent, pre-acclimatization and, in some instances, medications. CMS is characterized by excessive erythrocytosis and related clinical symptoms. In severe CMS, temporary or permanent relocation to low altitude is recommended. Future research should focus on more objective diagnostic tools to enable prompt treatment, improved identification of individual susceptibilities and effective acclimatization and prevention options.

medicine, general & internal
A trek to the top: a review of acute mountain sickness

M J Porcelli,G M Gugelchuk

Abstract:Acute mountain sickness (AMS) affects, to varying degrees, all travelers to high altitudes (elevations greater than 5280 feet). In a small percentage of patients, AMS can lead to high-altitude pulmonary edema (HAPE) or high-altitude cerebral edema (HACE). Symptoms of AMS range from a combination of headache, insomnia, anorexia, nausea, and dizziness, to more serious manifestations, such as vomiting, dyspnea, muscle weakness, oliguria, peripheral edema, and retinal hemorrhage. Although the primary cause of these symptoms is related to the reduced oxygen content and humidity of the ambient air at high altitudes, the physiologic pathway relating hypoxemia to AMS and its sequelae remains unclear. Tips on self-diagnosis and symptom recognition are critical elements to be included in educating patients who are contemplating a trip to high altitudes. Preventive strategies include allowing 2 days of acclimatization before engaging in strenuous exercise at high altitudes, avoiding alcohol, and increasing fluid intake. Conditioning exercise for patients older than 35 years is also recommended before departure. A high-carbohydrate, low-fat, low-salt diet can also aid in preventing the onset of AMS. Acetazolamide (125 mg two or three times daily, or once at bedtime) has also been shown to reduce susceptibility to AMS and the incidence of HAPE and HACE. Although effective in treating cerebral symptoms of AMS, dexamethasone is not routinely recommended as a prophylactic agent for AMS.
Acute high-altitude sickness

Andrew M Luks,Erik R Swenson,Peter Bärtsch

DOI: https://doi.org/10.1183/16000617.0096-2016

2017-01-31

Abstract:At any point 1-5 days following ascent to altitudes ≥2500 m, individuals are at risk of developing one of three forms of acute altitude illness: acute mountain sickness, a syndrome of nonspecific symptoms including headache, lassitude, dizziness and nausea; high-altitude cerebral oedema, a potentially fatal illness characterised by ataxia, decreased consciousness and characteristic changes on magnetic resonance imaging; and high-altitude pulmonary oedema, a noncardiogenic form of pulmonary oedema resulting from excessive hypoxic pulmonary vasoconstriction which can be fatal if not recognised and treated promptly. This review provides detailed information about each of these important clinical entities. After reviewing the clinical features, epidemiology and current understanding of the pathophysiology of each disorder, we describe the current pharmacological and nonpharmacological approaches to the prevention and treatment of these diseases.
Ultraviolet B-exposed and soluble factor-pre-incubated epidermal Langerhans cells fail to induce contact hypersensitivity and promote DNP-specific tolerance.

R. Dai,J. Streilein

DOI: https://doi.org/10.1111/1523-1747.EP12292099

IF: 7.59

1997-05-01

Journal of Investigative Dermatology

Abstract:Acute low-dose ultraviolet B (UVB) radiation impairs the induction of contact hypersensitivity (CH) and induces tolerance in UVB-susceptible strains of mice when dinitrofluorobenzene (DNFB) is applied to an irradiated skin surface. We are interested in learning the cellular and molecular bases for the existence of UVB susceptibility in certain strains of mice. CH was induced by subcutaneous injections into naive syngeneic C57BL/6 and BALB/c mice of dinitrophenyl (DNP)-derivatized Thy-1(+)-depleted epidermal cells enriched for Ia+ cells (LC/DNP, 2 x 10(4) cells per mouse). Tolerance was detected by applying 185 microg of DNFB epicutaneously to mice treated 2 wk earlier with a putative tolerating regimen and testing CH expression. We found that LC/DNP obtained from C57BL/6 skin 2 h after UVB irradiation (400 J per m2) failed to induce CH and induced DNP-specific tolerance instead; by contrast, similar cells obtained from same or even higher dose (400 J per m2 and 1200 J per m2) UVB-exposed BALB/c skin induced vigorous CH, and no tolerance was detected. In both C57BL/6 and BALB/c mice, Ia+-depleted EC/DNP neither sensitized naive syngeneic mice nor induced tolerance. LC/DNP prepared from unirradiated trunk skin of either C57BL/6 or BALB/c mice and pre-incubated in vitro for 2 h with cis-UCA, TNF-alpha, or IL-10 failed to induce intense CH; instead, all induced DNP-specific tolerance. Pre-incubation of similar LCs with alpha-MSH in vitro for 2 h also failed to induce CH but did not cause tolerance. Thus, single low-dose UVB irradiation alters the immunogenic and tolerogenic potentials of LCs only in UVB-susceptible mice; by contrast, pre-treatment of LCs with UVB-dependent soluble factors can achieve effects similar to UVB irradiation in both UVB-susceptible and -resistant strains of mice. These findings demonstrate that UVB susceptibility in mice may be determined by the production of UVB-dependent soluble factors within UVB-irradiated skin.
The impact of laws on HIV and STD prevention.

Cari Cason,Nan Orrock,K. Schmitt,J. Tesoriero,Z. Lazzarini,E. Sumartojo

Abstract:HIV and sexually transmitted diseases (STDs) are major public health problems in the United States. Since the start of the epidemic, nearly 800,000 persons have been reported with AIDS, and approximately 900,000 Americans are currently living with HIV infection. Each year, 15 million people in the United States become infected with one or more STDs. The direct and indirect costs of the major STDs--not including HIV infection--and their complications are estimated to total at least $10 billion annually. This article underscores the importance of law and other structural factors in the prevention and treatment of HIV and STDs. It describes state-level laws on STD screening, name-based reporting of STDs, name-based reporting of HIV and HIV partner notification implementation, and the impact of laws on STD and HIV risk behaviors and prevention services. More broadly, the article focuses on how the law influences the vulnerability or resilience of persons facing the risk of STDs, HIV infection, or AIDS.
High-altitude Cerebral Edema and High-altitude Pulmonary Edema Diagnosed in the Desert: A Case Report

Bryn Walsh,Suneil Agrawal

DOI: https://doi.org/10.5811/cpcem.3851

Abstract:Introduction: Acute mountain sickness, high-altitude pulmonary edema (HAPE), and high-altitude cerebral edema (HACE) are a spectrum of high-altitude conditions, with HACE being the most life-threatening. Most cases develop at altitudes of greater than 4,000 meters (∼13,000 feet) above sea level and after one to five days. Case report: A previously healthy 46-year-old female presented to the emergency department with ataxia, altered mental status, and vomiting that developed after rapidly ascending to ∼2,400 meters (∼7,800 feet) above sea level. She was treated for HACE and HAPE with resolution of her symptoms within 24 hours. Conclusion: High-altitude pulmonary edema and HACE can develop rapidly and at moderate altitudes. Expeditious recognition and treatment is imperative to avoid life-threatening complications.
Flying to high-altitude destinations: Is the risk of acute mountain sickness greater?

Johannes Burtscher,Erik R Swenson,Grégoire P Millet,Martin Burtscher,Peter H Hackett

DOI: https://doi.org/10.1093/jtm/taad011

2023-01-25

Journal of Travel Medicine

Abstract:Abstract Background Altitude sojourns increasingly attract individuals of all ages and different health statuses due to the appeal of high-altitude destinations worldwide and easy access to air travel. The risk of acute mountain sickness (AMS) when flying to high-altitude destinations remains underemphasized. Thus, this review aims to evaluate the altitude-dependent AMS incidence depending on the mode of ascending, e.g. by air vs terrestrial travel. Methods A literature search was performed to identify the observational studies assessing AMS incidence after acute ascent of primarily healthy adults to real high altitude. In addition, placebo arms of interventional trials evaluating the prophylactic efficacy of various drugs have been separately analysed to confirm or refute the findings from the observational studies. Linear regression analyses were used to evaluate the altitude-dependent AMS incidence. Results Findings of 12 observational studies, in which the AMS incidence in 11 021 individuals ascending to 19 different altitudes (2200–4559 m) was evaluated, revealed an impressive 4.5-fold steeper increase in the AMS incidence for air travel as compared with slower ascent modes, i.e. hiking or combined car and/or air travel and hiking. The higher AMS incidence following transportation by flight vs slower means was also confirmed in placebo-treated participants in 10 studies of drug prophylaxis against AMS. Conclusions Due to the short time span in going from low to high altitude, reduced acclimatization likely is the main reason for a higher AMS risk when travelling to high-altitude destinations by flight. To avoid frustrating travel experiences and health risks, appropriate and timely medical advice on how to prepare for air travel to high altitude is of vital importance. Effective preparation options include the use of modern pre-acclimatization strategies and pharmacological prophylaxis by acetazolamide or dexamethasone, or even considering alternate itineraries with more gradual ascent.

medicine, general & internal,infectious diseases,public, environmental & occupational health
Risk factors underlying high-altitude pulmonary edema in the Ecuadorian Andes

Karen Sánchez,Wilfre Machado,Anita Villafuerte,Santiago Ballaz

DOI: https://doi.org/10.21203/rs.3.rs-463193/v1

2021-08-19

Abstract:Abstract Background Ascent to high altitude (> 2500 m) exposes people to hypobaric atmospheric pressure and blood hypoxemia. It provokes a syndrome whose symptoms vary from the mild acute mountain sickness (AMS) to the life-threatening, high-altitude pulmonary edema (HAPE). This study analyzed the risk for developing high-altitude sickness in a group of HAPE patients (n = 59), which was contrasted against a group of AMS patients (n = 240) as the NO HAPE group, after sojourning above 4,000 m height. The objective of this retrospective was to analyse the factors contributing to the HAPE prevalence among travellers and dwellers of the Ecuadorian Andes. Methods AMS and HAPE groups were compared through demographic (ethnicity, sex, and age), environmental (permanent residence altitude and recent stay at sea-level), health status (vital signs), and blood analysis variables. The Cramer ́s V, simple logistic regression(SLR), and multiple logistic regression(MLR) analyses revealed patterns of significant associations. Results Analyses revealed that high-altitude indigenous residents were HAPE-prone, while mestizos living at sea level only had AMS. Blood pressure played a role in HAPE risk. Women were more tolerant to HAPE than men. Among indigenes , HAPE prevalence significantly rose after sojourning at sea level, a phenomenon called “reentry HAPE”. Conclusions In Andean indigenes , HAPE could be produced by a poor adaptation to high altitude, a high haemoglobin, and a blunted reactivity of blood pressure to environmentally-induced hypoxia. All the above gives support to the complex gene-environment interactions in the progress of HAPE, which may give some clues about of the etiopathogenesis of non-cardiogenic edema.
Recommendations for Women in Mountain Sports and Hypoxia Training/Conditioning

Johannes Burtscher,Antoine Raberin,Franck Brocherie,Davide Malatesta,Giorgio Manferdelli,Tom Citherlet,Bastien Krumm,Nicolas Bourdillon,Juliana Antero,Letizia Rasica,Martin Burtscher,Grégoire P. Millet

DOI: https://doi.org/10.1007/s40279-023-01970-6

IF: 11.928

2023-12-13

Sports Medicine

Abstract:The (patho-)physiological responses to hypoxia are highly heterogeneous between individuals. In this review, we focused on the roles of sex differences, which emerge as important factors in the regulation of the body's reaction to hypoxia. Several aspects should be considered for future research on hypoxia-related sex differences, particularly altitude training and clinical applications of hypoxia, as these will affect the selection of the optimal dose regarding safety and efficiency. There are several implications, but there are no practical recommendations if/how women should behave differently from men to optimise the benefits or minimise the risks of these hypoxia-related practices. Here, we evaluate the scarce scientific evidence of distinct (patho)physiological responses and adaptations to high altitude/hypoxia, biomechanical/anatomical differences in uphill/downhill locomotion, which is highly relevant for exercising in mountainous environments, and potentially differential effects of altitude training in women. Based on these factors, we derive sex-specific recommendations for mountain sports and intermittent hypoxia conditioning: (1) Although higher vulnerabilities of women to acute mountain sickness have not been unambiguously shown, sex-dependent physiological reactions to hypoxia may contribute to an increased acute mountain sickness vulnerability in some women. Adequate acclimatisation, slow ascent speed and/or preventive medication (e.g. acetazolamide) are solutions. (2) Targeted training of the respiratory musculature could be a valuable preparation for altitude training in women. (3) Sex hormones influence hypoxia responses and hormonal-cycle and/or menstrual-cycle phases therefore may be factors in acclimatisation to altitude and efficiency of altitude training. As many of the recommendations or observations of the present work remain partly speculative, we join previous calls for further quality research on female athletes in sports to be extended to the field of altitude and hypoxia.

sport sciences
An FT-IR study of the beta-amyloid conformation: standardization of aggregation grade.

Z. Szabó,É. Klement,K. Jost,Márta Zarándi,K. Soós,Botond Penke

DOI: https://doi.org/10.1006/BBRC.1999.1667

1999-11-19

Abstract:The aggregation of beta-amyloid peptides is very important for their neurotoxic effect; standardization of the aggregation grade is necessary for biological experiments. Measurement of aggregation with physicochemical methods is a difficult task. The present work revealed that FT-IR can be used for studying the aggregation properties of beta-amyloid peptides and the effects of environmental variables (solvent, pH, ions, and temperature) on aggregation. In dimethyl sulfoxide or hexafluoroisopropanol, amyloid peptides are in a monomeric state; on dilution with phosphate buffer just before measurement is made, aggregation begins. A detailed two-dimensional FT-IR correlation spectroscopic study was made of the conformational transitions that occur during the aggregation of beta-amyloid peptides. Two processes (random/helix-to-beta-sheet and aggregation of beta-sheets) and multiple conformational states were observed before the most stable form was attained. beta-Amyloid peptides undergo decomposition in basic buffers containing Ca(2+); this process should be avoided during aging experiments.
Mitral valve obstruction in a case of bacterial endocarditis due to Corynebacterium hofmanii: echocardiographic diagnosis.

S. Rubler,L. Harvey,A. Avitabile,T. Abenavoli

1982-10-01

Abstract:
Interventions for preventing high altitude illness: Part 3. Miscellaneous and non-pharmacological interventions.

Daniel Molano Franco,Víctor H Nieto Estrada,Alejandro G Gonzalez Garay,Arturo J Martí‐Carvajal,Ingrid Arevalo‐Rodriguez,Arturo J Martí-Carvajal,Ingrid Arevalo-Rodriguez

DOI: https://doi.org/10.1002/14651858.CD013315

IF: 8.4

2019-10-07

Cochrane Database of Systematic Reviews

Abstract:High altitude illness (HAI) is a term used to describe a group of mainly cerebral and pulmonary syndromes that can occur during travel to elevations above 2500 metres ( ̃ 8200 feet). Acute mountain sickness (AMS), high altitude cerebral oedema (HACE), and high altitude pulmonary oedema (HAPE) are reported as potential medical problems associated with high altitude ascent. In this, the third of a series of three reviews about preventive strategies for HAI, we assessed the effectiveness of miscellaneous and non‐pharmacological interventions. To assess the clinical effectiveness and adverse events of miscellaneous and non‐pharmacological interventions for preventing acute HAI in people who are at risk of developing high altitude illness in any setting. We searched the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, Embase, LILACS and the World Health Organization International Clinical Trials Registry Platform (WHO ICTRP) in January 2019. We adapted the MEDLINE strategy for searching the other databases. We used a combination of thesaurus‐based and free‐text search terms. We scanned the reference lists and citations of included trials and any relevant systematic reviews that we identified for further references to additional trials. We included randomized controlled trials conducted in any setting where non‐pharmacological and miscellaneous interventions were employed to prevent acute HAI, including preacclimatization measures and the administration of non‐pharmacological supplements. We included trials involving participants who are at risk of developing high altitude illness (AMS or HACE, or HAPE, or both). We included participants with, and without, a history of high altitude illness. We applied no age or gender restrictions. We included trials where the relevant intervention was administered before the beginning of ascent. We used the standard methodological procedures employed by Cochrane. We included 20 studies (1406 participants, 21 references) in this review. Thirty studies (14 ongoing, and 16 pending classification (awaiting)) will be considered in future versions of this suite of three reviews as appropriate. We report the results for the primary outcome of this review (risk of AMS) by each group of assessed interventions. Group 1. Preacclimatization and other measures based on pressure Use of simulated altitude or remote ischaemic preconditioning (RIPC) might not improve the risk of AMS on subsequent exposure to altitude, but this effect is uncertain (simulated altitude: risk ratio (RR) 1.18, 95% confidence interval (CI) 0.82 to 1.71; I2 = 0%; 3 trials, 140 participants; low‐quality evidence. RIPC: RR 3.0, 95% CI 0.69 to 13.12; 1 trial, 40 participants; low‐quality evidence). We found evidence of improvement of this risk using positive end‐expiratory pressure (PEEP), but this information was derived from a cross‐over trial with a limited number of participants (OR 3.67, 95% CI 1.38 to 9.76; 1 trial, 8 participants; low‐quality evidence). We found scarcity of evidence about the risk of adverse events for these interventions. Group 2. Supplements and vitamins Supplementation of antioxidants, medroxyprogesterone, iron or Rhodiola crenulata might not improve the risk of AMS on exposure to high altitude, but this effect is uncertain (antioxidants: RR 0.58, 95% CI 0.32 to 1.03; 1 trial, 18 participants; low‐quality evidence. Medroxyprogesterone: RR 0.71, 95% CI 0.48 to 1.05; I2 = 0%; 2 trials, 32 participants; low‐quality evidence. Iron: RR 0.65, 95% CI 0.38 to 1.11; I2 = 0%; 2 trials, 65 participants; low‐quality evidence. R crenulata : RR 1.00, 95% CI 0.78 to 1.29; 1 trial, 125 participants; low‐quality evidence). We found evidence of improvement of this risk with the administration of erythropoietin, but this information was extracted from a trial with issues related to risk of bias and imprecision (RR 0.41, 95% CI 0.20 to 0.84; 1 trial, 39 participants; very low‐quality evidence). Regarding administration of ginkgo biloba, we did not perform a pooled estimation of RR for AMS due to considerable heterogeneity between the included studies (I2 = 65%). RR estimates from the individual studies were conflicting (from 0.05 to 1.03; low‐quality evidence). We found scarcity of evidence about the risk of adverse events for these interventions. Group 3. Other comparisons We found heterogeneous evidence regarding the risk of AMS when ginkgo biloba was compared with acetazolamide (I2 = 63%). RR estimates from the individual studies were conflicting (estimations from 0.11 (95% CI 0.01 to 1.86) to 2.97 (95% CI 1.70 to 5.21); low‐quality evidence). We found evidence of improvement when ginkgo biloba was administered along with acetazolamide, but this information was derived from a single trial with issues associated to risk of bias (compared to ginkgo biloba alone: RR 0.43, 95% CI 0.26 to 0.71; 1 trial, 311 -Abstract Truncated-

medicine, general & internal
The effects of the menstrual cycle on the physiological responses to exercise in eumenorrheic women at high-altitude

Guia Tagliapietra,Tom Citherlet,Antoine Raberin,Giorgio Manferdelli,Bastien Krumm,Benjamin J. Narang,Nicolas Bourdillon,Tadej Debevec,Guido Giardini,Grégoire Millet

DOI: https://doi.org/10.36950/2024.2ciss077

2024-02-06

Current Issues in Sport Science (CISS)

Abstract:Introduction The acute mountain sickness (AMS) prevalence increases with altitude; i.e.,10-25% at 2,500 m and 50-85% at ~5,000 m (Bärtsch & Swenson, 2013). Women are more likely affected by AMS than men (Richalet et al., 2012). AMS can affect exercise performance. However, the effects of the menstrual cycle (MC) on physiological responses to exercise and on tolerance to high-altitude (HA) remain underexplored. It has been reported that ovarian hormones stimulate ventilation in normoxic conditions (Saaresranta & Polo, 2002). Early findings suggest that running economy is lower in the mid-luteal (ML) compared to the early-follicular (EF) phase in normoxia (Goldsmith & Glaister, 2020). However, cycling efficiency at HA has not been explored yet. Thus, we investigated the effects of acute HA exposure on ventilatory responses at rest and during exercise in healthy females during two different phases of their MC. Methods Sixteen eumenorrheic women (age: 33 ± 7 yr; MC length: 27 ± 2 days; not taking any hormonal contraceptive) took part in this study. First, over a 6-month period, the participants’ MC were monitored using a calendar method. Then, they reached the Torino Hut (3,375 m) by cable car and spent one night at HA on two different MC phases; i.e., during the early-follicular (EF; MC day 4 ± 1) and the mid-luteal (ML; day 20 ± 2) phases. Each time, they underwent a submaximal (1.2 W/kg) test on a cycle ergometer ~17 h after arrival at HA. In addition to this, participants filled in two questionnaires, the Lake Louise AMS Score and the Groningen Sleep Quality Scale, ~16 h after arrival at HA. Results Resting ventilation was significantly higher during EF compared to ML (15.2 ± 1.9 vs. 13.2 ± 2.5 L/min, p = 0.039), while no differences were found for ventilation during exercise (53.9 ± 13.2 vs. 53.5 ± 13.4 L/min, p = 0.695), cycling efficiency (21.7 ± 0.0% vs. 19.8 ± 0.0%, p = 0.244), saturation at rest (92.4 ± 1.3 vs. 91.3 ± 3.2%, p = 0.142) and during exercise (87.2 ± 5.7 vs. 89.0 ± 4.0%, p = 0.528). Moreover, no differences in the Lake Louise AMS (2.2 ± 1.5 vs. 1.7 ± 1.5, p = 0.266) or Groningen (8.0 ± 3.3 vs. 7.5 ± 3.4, p = 0.668) scores were noted between the two MC phases. Discussion/Conclusion Despite a slightly higher resting ventilation during EF, when both oestrogens and progesterone are at their lowest levels, there were no differences in ventilatory responses to exercise and in AMS between the different phases of the MC. Consequently, there is currently very little evidence to aptly recommend a specific MC phase for mountaineering or any other HA activities (Burtscher et al., 2023). Further investigations are requested to assess whether other physiological responses to HA may be influenced by hormonal variations. References Bärtsch, P., & Swenson, E. R. (2013). Acute high-altitude illnesses. New England Journal of Medicine, 368, 2294–2302. https://doi.org/10.1056/NEJMcp1214870 Burtscher, J., Raberin, A., Brocherie, F., Malatesta, D., Manferdelli, G., Citherlet, T., Krumm, B., Bourdillon, N., Antero, J., Rasica, L., Burtscher, M. & Millet, G. P. (2023). Recommendations for women in mountain sports and hypoxia training/conditioning. Sports Medicine. Advance online publication. https://doi.org/10.1007/s40279-023-01970-6 Goldsmith, E., & Glaister, M. (2020). The effect of the menstrual cycle on running economy. The Journal of Sports Medicine and Physical Fitness, 60(4), 610–617. https://doi.org/10.23736/s0022-4707.20.10229-9 Richalet, J.-P., Larmignat, P., Poitrine, E., Letournel, M., & Canouï-Poitrine, F. (2012). Physiological risk factors for severe high-altitude illness: A prospective cohort study. American Journal of Respiratory and Critical Care Medecine, 185(2), 192–198. https://doi.org/10.1164/rccm.201108-1396OC Saaresranta, T., & Polo, O. (2002). Hormones and breathing. American College of Chest Physicians, 122(6), 2165–2182. https://doi.org/10.1378/chest.122.6.2165
Network Analysis Reveals Distinct Clinical Syndromes Underlying Acute Mountain Sickness

David P. Hall,Ian J. C. MacCormick,Alex T. Phythian-Adams,Nina M. Rzechorzek,David Hope-Jones,Sorrel Cosens,Stewart Jackson,Matthew G. D. Bates,David J. Collier,David A. Hume,Thomas Freeman,A. A. Roger Thompson,John Kenneth Baillie

DOI: https://doi.org/10.1371/journal.pone.0081229

IF: 3.7

2014-01-22

PLoS ONE

Abstract:Acute mountain sickness (AMS) is a common problem among visitors at high altitude, and may progress to life-threatening pulmonary and cerebral oedema in a minority of cases. International consensus defines AMS as a constellation of subjective, non-specific symptoms. Specifically, headache, sleep disturbance, fatigue and dizziness are given equal diagnostic weighting. Different pathophysiological mechanisms are now thought to underlie headache and sleep disturbance during acute exposure to high altitude. Hence, these symptoms may not belong together as a single syndrome. Using a novel visual analogue scale (VAS), we sought to undertake a systematic exploration of the symptomatology of AMS using an unbiased, data-driven approach originally designed for analysis of gene expression. Symptom scores were collected from 292 subjects during 1110 subject-days at altitudes between 3650 m and 5200 m on Apex expeditions to Bolivia and Kilimanjaro. Three distinct patterns of symptoms were consistently identified. Although fatigue is a ubiquitous finding, sleep disturbance and headache are each commonly reported without the other. The commonest pattern of symptoms was sleep disturbance and fatigue, with little or no headache. In subjects reporting severe headache, 40% did not report sleep disturbance. Sleep disturbance correlates poorly with other symptoms of AMS (Mean Spearman correlation 0.25). These results challenge the accepted paradigm that AMS is a single disease process and describe at least two distinct syndromes following acute ascent to high altitude. This approach to analysing symptom patterns has potential utility in other clinical syndromes.

multidisciplinary sciences
Mountain sickness in altitude inhabitants of Latin America: A systematic review and meta-analysis

J Pierre Zila-Velasque,Pamela Grados-Espinoza,P Alejandra Goicochea-Romero,Gustavo Tapia-Sequeiros,J Enrique Pascual-Aguilar,Arturo J Ruiz-Yaringaño,Shamir Barros-Sevillano,Jhon Ayca-Mendoza,Wendy Nieto-Gutierrez

DOI: https://doi.org/10.1371/journal.pone.0305651

IF: 3.7

2024-09-24

PLoS ONE

Abstract:Objective: Chronic and acute mountain sickness is known worldwide, but most of the available information comes from the eastern continent (Himalayas) without taking into account the west which has the most recent group located at altitude, the Andes. The aim of this study was to synthesize the evidence on the prevalence of acute and chronic mountain sickness in Latin American countries (LATAM). Methods: A systematic search of the variables of interest was performed until July 8, 2023 in the Web of Science, Scopus, PubMed and Embase databases. We included studies that assessed the prevalence of mountain sickness in high-altitude inhabitants (>1500 m.a.s.l) who lived in a place more than 12 months. These were analyzed by means of a meta-analysis of proportions. To assess sources of heterogeneity, subgroup analyses and sensitivity analyses were performed by including only studies with low risk of bias and excluding extreme values (0 or 10,000 ratio). PROSPERO (CRD42021286504). Results: Thirty-nine cross-sectional studies (10,549 participants) met the inclusion criteria. We identified 5 334 and 2 945 events out of 10,000 with acute and chronic mountain sickness in LATAM countries. The most common physiological alteration was polycythemia (2,558 events), while cerebral edema was the less common (46 events). Clinical conditions were more prevalent at high altitudes for both types of MS. Conclusion: Acute mountain sickness (AMS) occurs approximately in 5 out of 10 people at high altitude, while chronic mountain sickness (CMS) occurs in 3 out of 10. The most frequent physiological alteration was polycythemia and the least frequent was cerebral edema.
Effect of penetration enhancers and iontophoresis on the ultrastructure and cholecystokinin-8 permeability through porcine skin.

K. Bhatia,S. Gao,T. Freeman,J. Singh

DOI: https://doi.org/10.1021/JS970023K

1997-09-01

Journal of Pharmacy and Science

Abstract:The present study explores the effect of chemical penetration enhancers and iontophoresis on the in vitro permeability of cholecystokinin-8 (CCK-8) through porcine epidermis and on the ultrastructural changes in stratum corneum as observed by transmission electron microscopy (TEM). Enhancer [i.e., ethanol (EtOH), and 10% oleic acid in combination with ethanol (OA/EtOH)] pretreatment significantly increased (p < 0.01) the permeability coefficient of CCK-8 in comparison with the control (pretreated epidermis without enhancer). Iontophoresis further increased the permeability of CCK-8 (p < 0.01) through the enhancer-pretreated epidermis in comparison with the control. These results showed the synergistic effect of iontophoresis and enhancers such as OA/EtOH that provides an additional driving force to maintain and control the target flux of CCK-8. The ultrastructure of stratum corneum treated with ethanol demonstrated a loss of structural components in the superficial stratum corneum cell layers. OA/EtOH transformed the highly compact cells of stratum corneum into a looser network of filaments, creating an increased free volume and greater intracellular surface area. Treatment of stratum corneum with OA/EtOH followed by iontophoresis resulted in further swelling of stratum corneum cell layers. In conclusion, OA/EtOH in combination with iontophoresis increased the permeability of CCK-8 by loosening and swelling of stratum corneum cell layers.

Influence of underfill materials on the reliability of coreless flip chip package

Menopause and High Altitude: A Scoping Review-UIAA Medical Commission Recommendations

Characteristics and enantiomeric analysis of chiral pyrethroids.

Research advances in pathogenesis and prophylactic measures of acute high altitude illness

Hormonal Contraception and Menstrual Cycle Control at High Altitude: A Scoping Review-UIAA Medical Commission Recommendations

Altitude illnesses

A trek to the top: a review of acute mountain sickness

Acute high-altitude sickness

Ultraviolet B-exposed and soluble factor-pre-incubated epidermal Langerhans cells fail to induce contact hypersensitivity and promote DNP-specific tolerance.

The impact of laws on HIV and STD prevention.

High-altitude Cerebral Edema and High-altitude Pulmonary Edema Diagnosed in the Desert: A Case Report

Flying to high-altitude destinations: Is the risk of acute mountain sickness greater?

Risk factors underlying high-altitude pulmonary edema in the Ecuadorian Andes

Recommendations for Women in Mountain Sports and Hypoxia Training/Conditioning

An FT-IR study of the beta-amyloid conformation: standardization of aggregation grade.

Mitral valve obstruction in a case of bacterial endocarditis due to Corynebacterium hofmanii: echocardiographic diagnosis.

Interventions for preventing high altitude illness: Part 3. Miscellaneous and non-pharmacological interventions.

The effects of the menstrual cycle on the physiological responses to exercise in eumenorrheic women at high-altitude

Network Analysis Reveals Distinct Clinical Syndromes Underlying Acute Mountain Sickness

Mountain sickness in altitude inhabitants of Latin America: A systematic review and meta-analysis

Effect of penetration enhancers and iontophoresis on the ultrastructure and cholecystokinin-8 permeability through porcine skin.